Moderna's stock soared after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer.
FILE - A sign marks an entrance to a Moderna building in Cambridge, Mass., on Monday, May 18, 2020. Shares of Merck and Moderna jumped early Tuesday, Dec. 13, 2022, after the drugmakers said a potential skin cancer vaccine they are developing using the same technology behind COVID-19 preventive shots did well in a mid-stage study.
The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of patients who had the cancer surgically removed. “We are very excited, we are moving very quickly with Merck onto phase 3 for this study,” Moderna CEO Stephane Bancel told CNBC Tuesday morning.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Merck, Moderna detail potential skin cancer vaccine progressMerck and Moderna said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had the tumors removed in surgery.
Leer más »
Moderna and Merck team-up to fight melanomaVaccine-maker Moderna has partnered with the biopharmaceutical company Merck to create an effective treatment for skin cancer
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Leer más »
Merck, Moderna share positive progress of potential skin cancer vaccineA potential skin cancer vaccine being developed using the same technology behind COVID shots fared well in a small study, the drug companies said. FOX13
Leer más »
Positive Moderna, Merck cancer vaccine data advances mRNA promise, shares riseAn experimental cancer vaccine from Moderna based on the messenger RNA technology used in successful COVID vaccines has been shown to work against melanoma.
Leer más »
Merck, Moderna detail potential skin cancer vaccine progressThe drugmakers said a combination of the vaccine and Merck’s immunotherapy Keytruda led to a statistically significant improvement in recurrence-free survival time in patients with phase three or four melanoma who had tumors removed in surgery.
Leer más »